Keith Speights, The
Motley Fool,•August
11, 2019
CVS
Health (NYSE: CVS) delivered some really good news to
investors last week with better-than-expected second-quarter results. The giant
healthcare company beat Wall Street analysts' revenue and earnings estimates.
CVS Health also raised its full-year 2019 guidance for the second quarter in a
row.
One
quarter doesn't make or break a stock. But it seems pretty clear now that CVS Health
is the best pharmacy stock on the market. Here are three rock-solid reasons
why.
1. It's out-innovating rivals
CVS
Health continues to beat its rivals in what I view as the most critical area
that will drive long-term growth: innovation. The company's executives talked
quite a bit in the Q2 conference call about one example of CVS
Health's innovation prowess, the HealthHUB concept.
HealthHUB
stores offer a wide range of healthcare services and technology solutions such
as health kiosks. Over one-fifth of these stores are dedicated to health
services, including durable medical equipment and products for sleep apnea and
diabetes care. The stores feature a "care concierge" to help customers
find the products and services they need.
Earlier
this year, CVS Health piloted a handful of HealthHUB locations. The company
plans to convert 1,500 stores to the HealthHUB concept by the end of 2021. CVS
Health CEO Larry Merlo said that the company's initial HealthHUB locations are
experiencing increased customer traffic as well as higher front-store sales and
MinuteClinic visits.
Another
promising innovation from CVS Health is its home hemodialysis system. The
company received FDA approval in July to begin a clinical trial of this system.
Merlo said CVS Health hopes to launch its home dialysis system in 2021.
2. Aetna is a huge plus
Some
expressed skepticism when CVS Health first announced its intention to acquire
Aetna. So far, though, the addition of the large health insurer to CVS Health's
lineup appears to be a huge plus.
Aetna's
business is booming thanks primarily to growth in its Medicare Advantage plans.
This helped boost CVS Health's top-line performance in Q2. The company is also
on track to realize $400 million in synergies this year, higher than its
previous estimate of between $300 million and $350 million. CVS Health projects
synergies of $800 million in 2020 and $900 million in 2021.
There
are also other ways that the integration of Aetna into its business should
benefit CVS Health. Merlo noted that the company recently launched a pilot
program of its NovoLogix technology platform that targets increasing medication
adherence with Aetna members and providers in 14 states. He said that CVS
Health plans to expand this pilot to more Aetna members and providers later in
2019. Increased medication adherence drives prescription volumes for the
company's pharmacy business. Also, Aetna could offer its members no or low
co-pays at MinuteClinics, steering more customers to CVS pharmacies.
Merlo
said that CVS Health is "building natural hedges" in its business
model. For example, a really nasty flu season would be a headwind for Aetna but
would increase sales for its retail pharmacy and pharmacy benefits management (PBM) businesses. On the
other hand, lower pharmacy spending would have the opposite impact.
3. It's expanding while other rivals are shrinking
Rite
Aid is much smaller than it once was. CVS Health's biggest
rival, Walgreens Boots Alliance, recently announced that it plans
to close around 200 stores across the U.S. But while these competitors are
shrinking, CVS continues to expand -- albeit at a slower pace than in the past.
Kevin
Hourican, who heads up the CVS pharmacy business, said that the company will
open 100 new stores this year compared to around 300 new stores annually a few
years ago. He also projected that the number of new store openings could
decline to 50 in 2020. A slower rate of expansion is better than a contraction,
though, especially if CVS Health can keep delivering solid earnings growth.
Still some risks
CVS
Health doesn't have a walk in the park to achieve success in the future. The
retail pharmacy business remains intensely competitive. Its PBM business could
come under fire down the road after winning a reprieve by the Trump
administration's decision to withdraw attempts to change rebate rules. If a
single-payer healthcare system is implemented as some presidential candidates
are proposing, it would hit CVS Health really hard.
These
risks could increase volatility for CVS Health's share price. However, they
don't override the fact that CVS Health has established a solid position as the
front-runner among pharmacy stocks.
Keith Speights has
no position in any of the stocks mentioned. The Motley Fool recommends CVS
Health. The Motley Fool has a disclosure
policy.
This
article was originally published on Fool.comhttps://news.yahoo.com/3-rock-solid-reasons-why-130000663.html
No comments:
Post a Comment